RT Book, Section A1 Thummel, Kenneth E. A1 Shen, Danny D. A1 Isoherranen, Nina A2 Brunton, Laurence L. A2 Chabner, Bruce A. A2 Knollmann, Björn C. SR Print(0) ID 1127864485 T1 Design and Optimization of Dosage Regimens: Pharmacokinetic Data T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e YR 2015 FD 2015 PB McGraw-Hill Education PP New York, NY SN 9780071624428 LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127864485 RD 2022/05/18 AB This appendix provides a summary of basic pharmacokinetic information pertaining to drugs that are in common clinical use and are delivered to the systemic circulation by parenteral or non-parenteral administration. Because of space limitations, this list cannot be exhaustive. Drugs designed exclusively for topical administration and not to be significantly absorbed into the bloodstream (e.g., ophthalmic and some dermal applications; Chapters 64 and 65) are not included. A few other selection criteria have influenced the makeup of the list, but, in general, the authors have tried to include one or more representative drugs in each of the therapeutic areas in this text, based on distinct mechanism(s) of action. In some instances, drugs may be excluded because pharmacokinetics are not relevant to their therapeutic management. An obvious case is when drug efficacy is not apparently correlated with drug concentration in a reversible fashion (e.g., some cytotoxic anticancer drugs). Also, for a number of therapeutic antibodies, the antibody is administered at a fixed dose at prolonged intervals that allows for its near complete clearance (e.g., infliximab).